KMCRIC

Lactobacillus paracasei F19 versus placebo for the prevention of proton pump inhibitor-induced bowel symptoms: a randomized clinical trial.

Compare D, Rocco A, Sgamato C, Coccoli P, Campo SM, Nazionale I, Larussa T, Luzza F, Chiodini P, Nardone G.

Dig Liver Dis.

2015

47(4)

273-9.

10.1016/j.dld.2015.01.004.

25660822

http://www.ncbi.nlm.nih.gov/pubmed/25660822

2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects
2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
Adolescent
Adult
Aged
Cross-Over Studies
Dietary Supplements*
Double-Blind Method
Female
Follow-Up Studies
Gastroesophageal Reflux/drug therapy
Humans
Irritable Bowel Syndrome/chemically induced
Irritable Bowel Syndrome/drug therapy*
Lactobacillus*
Male
Middle Aged
Probiotics/therapeutic use*
Proton Pump Inhibitors/adverse effects*
Proton Pump Inhibitors/therapeutic use
Treatment Outcome
Young Adult

Bloating; Flatulence; Lactobacillus paracasei subspecies Paracasei f19; Proton pump inhibitors

팽만; 장내가스; 락토바실러스 파라카제이 F19; 프로톤 펌프 억제제

없음

BACKGROUND:
Proton pump inhibitors may foster intestinal dysbiosis and related bowel symptoms.

AIM:
To evaluate the effect of Lactobacillus paracasei F19 on bowel symptom onset in patients on long-term proton pump inhibitors.

METHODS:
In this randomized, double-blind, placebo-controlled study, patients with typical gastroesophageal reflux disease symptoms receiving pantoprazole 40 mg/d for six months were randomly assigned to receive: (A) Lactobacillus paracasei F19 bid for three days/week for six months; (B) placebo bid for three days/week for six months; (C) Lactobacillus paracasei F19 bid for three days/week for three months and placebo bid for three days/week for the following three months; (D) placebo bid for three days/week for three months and Lactobacillus paracasei F19 bid for three days/week for the following three months. Bloating, flatulence, abdominal pain and bowel habit were assessed monthly.

RESULTS:
100/312 patients were enrolled. In the parallel groups, the treatment-by-time interaction affected bloating (p = 0.015), while Lactobacillus paracasei F19 treatment alone affected flatulence (p = 0.011). Moreover, the treatment-by-time interaction significantly affected the mean score of bloating (p = 0.01) and flatulence (p < 0.0001), the mean stool form (p = 0.03) and mean stool frequency/week (p = 0.016). Analysis of the cross-over groups, limited to the first three months because of carry-over effect, confirmed these results.

CONCLUSION:
Lactobacillus paracasei F19 supplementation prevents bowel symptom onset in patients on long-term proton pump inhibitors.

영어